The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure
Patients with multiple myeloma and end-stage renal failure on dialysis are frequently not considered eligible for high-dose therapy (HDT) due to higher transplant-related mortality (TRM). Our aim was to evaluate the toxicity and survival of dialysis-dependent patients after HDT with melphalan (100 m...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[November, 2006]
|
| In: |
Haematologica, the hematology journal
Year: 2006, Volume: 91, Issue: 11, Pages: 1555-1558 |
| ISSN: | 1592-8721 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/4218 Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/%x 
|
| Author Notes: | Marc S. Raab, Iris Breitkreutz, Michael Hundemer, Axel Benner, Jens Klaus, Ute Hegenbart, Thomas Moehler, Anthony D. Ho, Martin Zeier, Hartmut Goldschmidt |
| Summary: | Patients with multiple myeloma and end-stage renal failure on dialysis are frequently not considered eligible for high-dose therapy (HDT) due to higher transplant-related mortality (TRM). Our aim was to evaluate the toxicity and survival of dialysis-dependent patients after HDT with melphalan (100 mg/m(2)) compared to those of patients without renal insufficiency (melphalan 200 mg/m(2)) in a matched pairs analysis of 34 patients. No significant differences were observed between hematologic toxicity, TRM or disease response. Dialysis patients showed comparable event-free and overall survival. They required significantly extended intravenous antibiotic treatment and longer hospitalization. Thus, melphalan 100 mg/m2 is less toxic, yet equally efficient and improves the prognosis of this group of patients. |
|---|---|
| Item Description: | Gesehen am 09.11.2021 DOI fehlerhaft |
| Physical Description: | Online Resource |
| ISSN: | 1592-8721 |